Wilson, Latham Tapped for $208 Million Biotech Deal
SAN FRANCISCO — Attorneys from Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised on genomics technology firm Fluidigm Corp.'s $208 million acquisition of DVS Sciences Inc., which makes a device used to analyze single cells in biological research.
This content has been archived. It is available exclusively through our partner LexisNexis®.
To view this content, please continue to LexisAdvance®.
Not a LexisAdvance® Subscriber? Subscribe Now
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via LexisAdvance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
For questions call 1-877-256-2472 or contact us at firstname.lastname@example.org